ViiV Healthcare
ViiV’s two-drug regimen gets EU approval for HIV-1
May 22, 2018Manufacturing and Production, Sales and Marketing EMA, EU, Europe, HIV, Juluca, ViiV Healthcare, pharma
ViiV Healthcare has announced that its HIV therapy Juluca (dolutegravir/rilpivirine) has been awarded marketing authorisation in the EU from the …
FDA approves Gilead’s Biktarvy for HIV as Viiv Healthcare launches patent lawsuit
February 8, 2018Sales and Marketing Biktarvy, FDA, GSK, Gilead, HIV, Pfizer, Shionogi, US, ViiV Healthcare, descovy, pharma
Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.
FDA approves first-ever two-drug HIV regimen, GSK’s Juluca
November 22, 2017Research and Development, Sales and Marketing AIDS, FDA, GSK, Gilead, GlaxoSmithKilne, HIV, Juluca, ViiV Healthcare, pharma
GlaxoSmithKline has announced that the FDA has awarded US marketing authorisation to the first two-drug regimen in the treatment of …
Monthly injectable HIV treatment proves as effective as traditional daily pill regimen
July 24, 2017Research and Development, Sales and Marketing AIDS, HIV, Janssen, ViiV Healthcare, biotech, drugs, pharma, pharmaceuticals
New early trial data suggests that current daily HIV pill regimens could be replaced with injections which slowly release medication …
ViiV Healthcare launches Phase III trial for combo HIV treatment
August 16, 2016Research and Development Dolutegravir, HIV, Tivicay, ViiV Healthcare, epivir, lamivudine, phase III
The Pfizer/GSK spin off ViiV Healthcare has announced the beginning of a Phase III evaluating Tivicay (dolutegravir) and Epivir (lamivudine) …
New data shows superior viral suppression for Triumeq in women with HIV
July 18, 2016Manufacturing and Production, Research and Development Triumeq, ViiV Healthcare
ViiV Healthcare has presented late-stage data showing superior efficacy for combination treatment Triumeq (dolutegravir/abacavir/lamivudine) compared with atazanavir, plus other treatments, …
ViiV and Janssen to test new HIV regimen in Phase III trial
January 7, 2016Manufacturing and Production, Medical Communications, Research and Development Edurant, HIV, Janssen, ViiV Healthcare, cabotegravir, collaboration, phase III, rilpivirine
Janssen has formalised its collaboration with ViiV Healthcare on the Phase III development and commercialisation of a two-drug regimen to …
ViiV Healthcare to acquire Bristol-Myers Squibb’s HIV pipeline drugs
December 18, 2015Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, HIV, ViiV, ViiV Healthcare
Specialist HIV company ViiV Healthcare has agreed deals worth up to $1.46 billion to purchase Bristol-Myers Squibb’s late stage HIV …
Pharma’s reputation ‘is worsening among patients’
February 10, 2015Medical Communications, Research and Development, Sales and Marketing HIV, ViiV Healthcare, patientview, pharma, reputation, transparency
Only around four in ten patients believe pharma has a good reputation and many companies are failing to win patient …
David Redfern appointed ViiV chairman
February 28, 2011Research and Development, Sales and Marketing David Redfern, GSK, GlaxoSmithKline, Pfizer, ViiV, ViiV Healthcare, appointment, research and development, sales and marketing
David Redfern has been appointed as chairman of ViiV Healthcare, the joint GlaxoSmithKline-Pfizer venture focused on HIV.
